These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1247 related articles for article (PubMed ID: 10985881)

  • 1. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
    Vaziri SA; Krumroy LM; Rostai M; Casey G
    Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology.
    Kerner R; Sabo E; Gershoni-Baruch R; Beck D; Ben-Izhak O
    Gynecol Oncol; 2005 Nov; 99(2):367-75. PubMed ID: 16051332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
    Ligtenberg MJ; Hogervorst FB; Willems HW; Arts PJ; Brink G; Hageman S; Bosgoed EA; Van der Looij E; Rookus MA; Devilee P; Vos EM; Wigbout G; Struycken PM; Menko FH; Rutgers EJ; Hoefsloot EH; Mariman EC; Brunner HG; Van 't Veer LJ
    Br J Cancer; 1999 Mar; 79(9-10):1475-8. PubMed ID: 10188893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
    Vahteristo P; Eerola H; Tamminen A; Blomqvist C; Nevanlinna H
    Br J Cancer; 2001 Mar; 84(5):704-8. PubMed ID: 11237395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.
    Grzybowska E; Zientek H; Jasinska A; Rusin M; Kozlowski P; Sobczak K; Sikorska A; Kwiatkowska E; Gorniak L; Kalinowska E; Utracka-Hutka B; Wloch J; Chmielik E; Krzyzosiak WJ
    Hum Mutat; 2000 Dec; 16(6):482-90. PubMed ID: 11102977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
    Goshen R; Chu W; Elit L; Pal T; Hakimi J; Ackerman I; Fyles A; Mitchell M; Narod SA
    Gynecol Oncol; 2000 Dec; 79(3):477-81. PubMed ID: 11104623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
    Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
    Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
    Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women.
    Noguchi S; Kasugai T; Miki Y; Fukutomi T; Emi M; Nomizu T
    Cancer; 1999 May; 85(10):2200-5. PubMed ID: 10326698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.